Advertisement

Current Diabetes Reports

, Volume 13, Issue 5, pp 669–678 | Cite as

Hypoglycemia in Patients with Type 1 Diabetes: Epidemiology, Pathogenesis, and Prevention

  • Omodele Awoniyi
  • Rabia Rehman
  • Samuel Dagogo-JackEmail author
Treatment of Type 1 Diabetes (JR Unger, Section Editor)

Abstract

Hypoglycemia is uncommon in the general, nondiabetic population but occurs frequently in persons with diabetes treated with insulin or insulin secretagogues. Thus, iatrogenic hypoglycemia explains the majority of cases among persons with type 1 diabetes (T1DM). Since T1DM is characterized by absolute insulin dependence, the current imperfections in insulin replacement therapies often lead to a mismatch between caloric supply and circulating insulin levels, thus increasing the risk for glycemic fluctuations. Hypoglycemia is the limiting factor to excellent glycemic control in insulin-treated subjects. Intensification of glycemic control was associated with a 300 % increase in the rate of hypoglycemia in the Diabetes Control and Complications Trial. Recent measurements using continuous glucose monitoring reveal an alarming rate of daytime and nocturnal episodes of hypoglycemia in patients with T1DM. Etiological factors underlying hypoglycemia in T1DM include predictable triggers (skipped meals, exercise, insulin over dosage) as well as defective counterregulation, a component of hypoglycemia-associated autonomic failure.

Keywords

Type 1 diabetes mellitus Hemoglobin A1c Iatrogenic hypoglycemia Epidemiology Risk factors Pathophysiology Defective counterregulation Hypoglycemia unawareness Hypoglycemia-associated autonomic failure Syndrome Insulinemia Prevention Monitoring Education Diet Exercise Medications Pathogenesis 

Notes

Acknowledgment

Dr. Samuel Dagogo-Jack is supported in part by grants from NIH (DK67269, DK62203, DK48411, DK 98246).

Compliance with Ethics Guidelines

Conflict of Interest

Omodele Awoniyi, Rabia Rehman, and Samuel Dagogo-Jack declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Crofford OB. Diabetes control and complications. Annu Rev Med. 1995;46:267–79.PubMedCrossRefGoogle Scholar
  2. 2.
    Dagogo-Jack S. Hypoglycemia in type 1 diabetes mellitus: pathophysiology and prevention. Treat Endocrinol. 2004;3(2):91–103.PubMedCrossRefGoogle Scholar
  3. 3.
    O'Connell SM, Cooper MN, Bulsara MK, Davis EA, Jones TW. Reducing rates of severe hypoglycemia in a population-based cohort of children and adolescents with type 1 diabetes over the decade 2000-2009. Diabetes Care. 2011;34(11):2379–80.PubMedCrossRefGoogle Scholar
  4. 4.
    • Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the american diabetes association and the endocrine society. Diabetes Care. 2013;36(5):1384–95. This recent report provides a comprehensive review on hypoglycemia in diabetes, addressing not only the clinical implications, but also the conventional and emerging strategies for its prevention.PubMedCrossRefGoogle Scholar
  5. 5.
    Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008;57(12):3169–76.PubMedCrossRefGoogle Scholar
  6. 6.
    Cryer PE. Hypoglycemia in type 1 diabetes mellitus. Endocrinol Metab Clin North Am. 2010;39(3):641–54.PubMedCrossRefGoogle Scholar
  7. 7.
    Workgroup on Hypoglycemia ADA. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245–9.CrossRefGoogle Scholar
  8. 8.
    Cryer PE. Banting Lecture. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes. 1994;43(11):1378–89.PubMedCrossRefGoogle Scholar
  9. 9.
    McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. Diabet Med. 2001;18(9):690–705.PubMedCrossRefGoogle Scholar
  10. 10.
    Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia. 2002;45(7):937–48.PubMedCrossRefGoogle Scholar
  11. 11.
    Cryer PE. Hypoglycemia risk reduction in type 1 diabetes. Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S412–23.PubMedCrossRefGoogle Scholar
  12. 12.
    Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med. 1991;90(4):450–9.Google Scholar
  13. 13.
    Bulsara MK, Holman CD, Davis EA, Jones TW. The impact of a decade of changing treatment on rates of severe hypoglycemia in a population-based cohort of children with type 1 diabetes. Diabetes Care. 2004;27(10):2293–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26(4):1176–80.PubMedCrossRefGoogle Scholar
  15. 15.
    Group UKHS. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140–7.CrossRefGoogle Scholar
  16. 16.
    Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med. 2005;22(6):749–55.PubMedCrossRefGoogle Scholar
  17. 17.
    Cryer PE. Hypoglycemia-associated autonomic failure in diabetes. Am J Physiol Endocrinol Metab. 2001;281(6):E1115–21.PubMedGoogle Scholar
  18. 18.
    Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, Hougaard P, Thorsteinsson B. Prediction of severe hypoglycaemia by angiotensin-converting enzyme activity and genotype in type 1 diabetes. Diabetologia. 2003;46(1):89–96.PubMedGoogle Scholar
  19. 19.
    Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, Hougaard P, Thorsteinsson B. Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus. Lancet. 2001;357(9264):1248–53.PubMedCrossRefGoogle Scholar
  20. 20.
    Bulsara MK, Holman CD, van Bockxmeer FM, Davis EA, Gallego PH, Beilby JP, et al. The relationship between ACE genotype and risk of severe hypoglycaemia in a large population-based cohort of children and adolescents with type 1 diabetes. Diabetologia. 2007;50(5):965–71.PubMedCrossRefGoogle Scholar
  21. 21.
    Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94(3):709–28.PubMedCrossRefGoogle Scholar
  22. 22.
    Harjutsalo V, Forsblom C, Groop PH. Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study. BMJ. 2011;343:d5364.PubMedCrossRefGoogle Scholar
  23. 23.
    Asao K, Sarti C, Forsen T, Hyttinen V, Nishimura R, Matsushima M, et al. Long-term mortality in nationwide cohorts of childhood-onset type 1 diabetes in Japan and Finland. Diabetes Care. 2003;26(7):2037–42.PubMedCrossRefGoogle Scholar
  24. 24.
    The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977–86.Google Scholar
  25. 25.
    Shafiee G, Mohajeri-Tehrani M, Pajouhi M, Larijani B. The importance of hypoglycemia in diabetic patients. J Diabetes Metab Disord. 2012;11(1):17.PubMedCrossRefGoogle Scholar
  26. 26.
    Ha WC, Oh SJ, Kim JH, Lee JM, Chang SA, Sohn TS, et al. Severe hypoglycemia is a serious complication and becoming an economic burden in diabetes. Diabetes Metab J. 2012;36(4):280–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Ginde AA, Espinola JA, Camargo Jr CA. Trends and disparities in U.S. emergency department visits for hypoglycemia, 1993-2005. Diabetes Care. 2008;31(3):511–3.PubMedCrossRefGoogle Scholar
  28. 28.
    Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002–12.PubMedCrossRefGoogle Scholar
  29. 29.
    Rhoads GG, Orsini LS, Crown W, Wang S, Getahun D, Zhang Q. Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes. J Occup Environ Med. 2005;47(5):447–52.PubMedCrossRefGoogle Scholar
  30. 30.
    Snell-Bergeon JK, Wadwa RP. Hypoglycemia, diabetes, and cardiovascular disease. Diabetes Technol Ther. 2012;14 Suppl 1:S51–8.PubMedGoogle Scholar
  31. 31.
    Marques JL, George E, Peacey SR, Harris ND, Macdonald IA, Cochrane T, et al. Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med. 1997;14(8):648–54.PubMedCrossRefGoogle Scholar
  32. 32.
    Frier BM. Morbidity of hypoglycemia in type 1 diabetes. Diabetes Res Clin Pract. 2004;65 Suppl 1:S47–52.PubMedCrossRefGoogle Scholar
  33. 33.
    Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes–the 'dead in bed' syndrome revisited. Diabetologia. 2009;52(1):42–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Razavi Nematollahi L, Kitabchi AE, Stentz FB, Wan JY, Larijani BA, Tehrani MM, et al. Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism. 2009;58(4):443–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Gimenez M, Gilabert R, Monteagudo J, Alonso A, Casamitjana R, Pare C, et al. Repeated episodes of hypoglycemia as a potential aggravating factor for preclinical atherosclerosis in subjects with type 1 diabetes. Diabetes Care. 2011;34(1):198–203.PubMedCrossRefGoogle Scholar
  36. 36.
    Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008;24(5):353–63.PubMedCrossRefGoogle Scholar
  37. 37.
    Oyer DS. The science of hypoglycemia in patients with diabetes. Curr Diabetes Rev. 2013;9(3):195–208.PubMedCrossRefGoogle Scholar
  38. 38.
    Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ. 2011;14(5):646–55.PubMedCrossRefGoogle Scholar
  39. 39.
    Cox DJ, Kovatchev B, Vandecar K, Gonder-Frederick L, Ritterband L, Clarke W. Hypoglycemia preceding fatal car collisions. Diabetes Care. 2006;29(2):467–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011;14(5):665–71.PubMedCrossRefGoogle Scholar
  41. 41.
    Noguchi R, Kubota H, Yugi K, Toyoshima Y, Komori Y, Soga T, et al. The selective control of glycolysis, gluconeogenesis and glycogenesis by temporal insulin patterns. Mol Syst Biol. 2013;9:664.PubMedCrossRefGoogle Scholar
  42. 42.
    Choi SM, Tucker DF, Gross DN, Easton RM, DiPilato LM, Dean AS, et al. Insulin regulates adipocyte lipolysis via an Akt-independent signaling pathway. Mol Cell Biol. 2010;30(21):5009–20.PubMedCrossRefGoogle Scholar
  43. 43.
    Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschop MH. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010;6(12):689–97.PubMedCrossRefGoogle Scholar
  44. 44.
    Pegorier JP, Garcia-Garcia MV, Prip-Buus C, Duee PH, Kohl C, Girard J. Induction of ketogenesis and fatty acid oxidation by glucagon and cyclic AMP in cultured hepatocytes from rabbit fetuses. Evidence for a decreased sensitivity of carnitine palmitoyltransferase I to malonyl-CoA inhibition after glucagon or cyclic AMP treatment. Biochem J. 1989;264(1):93–100.PubMedGoogle Scholar
  45. 45.
    Cryer PE. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012;153(3):1039–48.PubMedCrossRefGoogle Scholar
  46. 46.
    Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26(6):1902–12.PubMedCrossRefGoogle Scholar
  47. 47.
    Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I, et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol. 1991;260(1 Pt 1):E67–74.PubMedGoogle Scholar
  48. 48.
    Clarke WL, Gonder-Frederick LA, Richards FE, Cryer PE. Multifactorial origin of hypoglycemic symptom unawareness in IDDM. Association with defective glucose counterregulation and better glycemic control. Diabetes. 1991;40(6):680–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Bakatselos SO. Hypoglycemia unawareness. Diabetes Res Clin Pract. 2011;93 Suppl 1:S92–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Raju B, Cryer PE. Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the intraislet insulin hypothesis in humans. Diabetes. 2005;54(3):757–64.PubMedCrossRefGoogle Scholar
  51. 51.
    Cryer PE. Hypoglycemia in diabetes: pathophysiological mechanisms and diurnal variation. Prog Brain Res. 2006;153:361–5.PubMedCrossRefGoogle Scholar
  52. 52.
    Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest. 1993;91(3):819–28.PubMedCrossRefGoogle Scholar
  53. 53.
    Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes. 2005;54(12):3592–601.PubMedCrossRefGoogle Scholar
  54. 54.
    Cryer PE. Hypoglycemia unawareness in IDDM. Diabetes Care. 1993;16 Suppl 3:40–7.PubMedGoogle Scholar
  55. 55.
    DeRosa MA, Cryer PE. Hypoglycemia and the sympathoadrenal system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol Endocrinol Metab. 2004;287(1):E32–41.PubMedCrossRefGoogle Scholar
  56. 56.
    Cryer PE. Mechanisms of sympathoadrenal failure and hypoglycemia in diabetes. J Clin Invest. 2006;116(6):1470–3.PubMedCrossRefGoogle Scholar
  57. 57.
    • Reno CM, Litvin M, Clark AL, Fisher SJ. Defective counterregulation and hypoglycemia unawareness in diabetes: mechanisms and emerging treatments. Endocrinol Metab Clin North Am. 2013;42(1):15–38. This article provides a thorough review of the pathophysiologic mechanisms implicated in defective counterregulation and hypoglycemia unawareness, as well as emerging treatment options.PubMedCrossRefGoogle Scholar
  58. 58.
    Banarer S, Cryer PE. Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: reduced awakening from sleep during hypoglycemia. Diabetes. 2003;52(5):1195–203.PubMedCrossRefGoogle Scholar
  59. 59.
    McGregor VP, Greiwe JS, Banarer S, Cryer PE. Limited impact of vigorous exercise on defenses against hypoglycemia: relevance to hypoglycemia-associated autonomic failure. Diabetes. 2002;51(5):1485–92.PubMedCrossRefGoogle Scholar
  60. 60.
    Davis SN, Shavers C, Costa F, Mosqueda-Garcia R. Role of cortisol in the pathogenesis of deficient counterregulation after antecedent hypoglycemia in normal humans. J Clin Invest. 1996;98(3):680–91.PubMedCrossRefGoogle Scholar
  61. 61.
    Flanagan DE, Keshavarz T, Evans ML, Flanagan S, Fan X, Jacob RJ, et al. Role of corticotrophin-releasing hormone in the impairment of counterregulatory responses to hypoglycemia. Diabetes. 2003;52(3):605–13.PubMedCrossRefGoogle Scholar
  62. 62.
    Raju B, McGregor VP, Cryer PE. Cortisol elevations comparable to those that occur during hypoglycemia do not cause hypoglycemia-associated autonomic failure. Diabetes. 2003;52(8):2083–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Koranyi L, Bourey RE, James D, Mueckler M, Fiedorek Jr FT, Permutt MA. Glucose transporter gene expression in rat brain: Pretranslational changes associated with chronic insulin-induced hypoglycemia, fasting, and diabetes. Mol Cell Neurosci. 1991;2(3):244–52.PubMedCrossRefGoogle Scholar
  64. 64.
    Segel SA, Fanelli CG, Dence CS, Markham J, Videen TO, Paramore DS, et al. Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia. Diabetes. 2001;50(8):1911–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Boyle PJ, Nagy RJ, O'Connor AM, Kempers SF, Yeo RA, Qualls C. Adaptation in brain glucose uptake following recurrent hypoglycemia. Proc Natl Acad Sci U S A. 1994;91(20):9352–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Levin BE, Becker TC, Eiki J, Zhang BB, Dunn-Meynell AA. Ventromedial hypothalamic glucokinase is an important mediator of the counterregulatory response to insulin-induced hypoglycemia. Diabetes. 2008;57(5):1371–9.PubMedCrossRefGoogle Scholar
  67. 67.
    McCrimmon RJ, Fan X, Ding Y, Zhu W, Jacob RJ, Sherwin RS. Potential role for AMP-activated protein kinase in hypoglycemia sensing in the ventromedial hypothalamus. Diabetes. 2004;53(8):1953–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Chan O, Paranjape S, Czyzyk D, Horblitt A, Zhu W, Ding Y, et al. Increased GABAergic output in the ventromedial hypothalamus contributes to impaired hypoglycemic counterregulation in diabetic rats. Diabetes. 2011;60(5):1582–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Matveyenko AV, Bohland M, Saberi M, Donovan CM. Portal vein hypoglycemia is essential for full induction of hypoglycemia-associated autonomic failure with slow-onset hypoglycemia. Am J Physiol Endocrinol Metab. 2007;293(3):E857–64.PubMedCrossRefGoogle Scholar
  70. 70.
    Arbelaez AM, Powers WJ, Videen TO, Price JL, Cryer PE. Attenuation of counterregulatory responses to recurrent hypoglycemia by active thalamic inhibition: a mechanism for hypoglycemia-associated autonomic failure. Diabetes. 2008;57(2):470–5.PubMedCrossRefGoogle Scholar
  71. 71.
    Szepietowska B, Zhu W, Chan O, Horblitt A, Dziura J, Sherwin RS. Modulation of beta-adrenergic receptors in the ventromedial hypothalamus influences counterregulatory responses to hypoglycemia. Diabetes. 2011;60(12):3154–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Realsen JM, Chase HP. Recent advances in the prevention of hypoglycemia in type 1 diabetes. Diabetes Technol Ther. 2011;13(12):1177–86.PubMedCrossRefGoogle Scholar
  73. 73.
    Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care. 1994;17(7):697–703.PubMedCrossRefGoogle Scholar
  74. 74.
    Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes. 1994;43(12):1426–34.PubMedCrossRefGoogle Scholar
  75. 75.
    Yeh HC, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012;157(5):336–47.PubMedCrossRefGoogle Scholar
  76. 76.
    Cryer PE. Preventing hypoglycaemia: what is the appropriate glucose alert value? Diabetologia. 2009;52(1):35–7.PubMedCrossRefGoogle Scholar
  77. 77.
    Standards of medical care in diabetes--2013. Diabetes Care. 2013;36 Suppl 1:S11–66.Google Scholar
  78. 78.
    Kovatchev BP, Cox DJ, Farhy LS, Straume M, Gonder-Frederick L, Clarke WL. Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose. J Clin Endocrinol Metab. 2000;85(11):4287–92.PubMedCrossRefGoogle Scholar
  79. 79.
    Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359(14):1464–76.PubMedCrossRefGoogle Scholar
  80. 80.
    Kaufman FR, Austin J, Neinstein A, Jeng L, Halvorson M, Devoe DJ, et al. Nocturnal hypoglycemia detected with the Continuous Glucose Monitoring System in pediatric patients with type 1 diabetes. J Pediatr. 2002;141(5):625–30.PubMedCrossRefGoogle Scholar
  81. 81.
    Beck RW, Hirsch IB, Laffel L, Tamborlane WV, Bode BW, Buckingham B, et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009;32(8):1378–83.PubMedCrossRefGoogle Scholar
  82. 82.
    Cox DJ, Gonder-Frederick L, Ritterband L, Clarke W, Kovatchev BP. Prediction of severe hypoglycemia. Diabetes Care. 2007;30(6):1370–3.PubMedCrossRefGoogle Scholar
  83. 83.
    Cox DJ, Gonder-Frederick L, Polonsky W, Schlundt D, Kovatchev B, Clarke W. Blood glucose awareness training (BGAT-2): long-term benefits. Diabetes Care. 2001;24(4):637–42.PubMedCrossRefGoogle Scholar
  84. 84.
    Cox DJ, Kovatchev B, Koev D, Koeva L, Dachev S, Tcharaktchiev D, et al. Hypoglycemia anticipation, awareness and treatment training (HAATT) reduces occurrence of severe hypoglycemia among adults with type 1 diabetes mellitus. Int J Behav Med. 2004;11(4):212–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Cox D, Clarke W, Gonder-Frederick L, Kovatchev B. Driving mishaps and hypoglycaemia: risk and prevention. Int J Clin Pract Suppl. 2001;123:38–42.PubMedGoogle Scholar
  86. 86.
    Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care. 2003;26 Suppl 1:S51–61.PubMedGoogle Scholar
  87. 87.
    Cryer PE, Fisher JN, Shamoon H. Hypoglycemia. Diabetes Care. 1994;17(7):734–55.PubMedGoogle Scholar
  88. 88.
    Detlofson I, Kroon M, Aman J. Oral bedtime cornstarch supplementation reduces the risk for nocturnal hypoglycaemia in young children with type 1 diabetes. Acta Paediatr. 1999;88(6):595–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Kaufman FR, Halvorson M, Kaufman ND. A randomized, blinded trial of uncooked cornstarch to diminish nocturnal hypoglycemia at diabetes camp. Diabetes Res Clin Pract. 1995;30(3):205–9.PubMedCrossRefGoogle Scholar
  90. 90.
    Chipkin SR, Klugh SA, Chasan-Taber L. Exercise and diabetes. Cardiol Clin. 2001;19(3):489–505.PubMedCrossRefGoogle Scholar
  91. 91.
    Zinman B, Ruderman N, Campaigne BN, Devlin JT, Schneider SH. Physical activity/exercise and diabetes mellitus. Diabetes Care. 2003;26 Suppl 1:S73–7.PubMedGoogle Scholar
  92. 92.
    Heller SR, Colagiuri S, Vaaler S, Wolffenbuttel BH, Koelendorf K, Friberg HH, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabet Med. 2004;21(7):769–75.PubMedCrossRefGoogle Scholar
  93. 93.
    Brunelle BL, Llewelyn J, Anderson Jr JH, Gale EA, Koivisto VA. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care. 1998;21(10):1726–31.PubMedCrossRefGoogle Scholar
  94. 94.
    Linkeschova R, Raoul M, Bott U, Berger M, Spraul M. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med. 2002;19(9):746–51.PubMedCrossRefGoogle Scholar
  95. 95.
    Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet. 1994;344(8918):283–7.PubMedCrossRefGoogle Scholar
  96. 96.
    Paty BW, Lanz K, Kendall DM, Sutherland DE, Robertson RP. Restored hypoglycemic counterregulation is stable in successful pancreas transplant recipients for up to 19 years after transplantation. Transplantation. 2001;72(6):1103–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Leitao CB, Tharavanij T, Cure P, Pileggi A, Baidal DA, Ricordi C, et al. Restoration of hypoglycemia awareness after islet transplantation. Diabetes Care. 2008;31(11):2113–5.PubMedCrossRefGoogle Scholar
  98. 98.
    Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355(13):1318–30.PubMedCrossRefGoogle Scholar
  99. 99.
    Meloche RM. Transplantation for the treatment of type 1 diabetes. World J Gastroenterol. 2007;13(47):6347–55.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Omodele Awoniyi
    • 1
  • Rabia Rehman
    • 1
  • Samuel Dagogo-Jack
    • 1
    Email author
  1. 1.Department of Medicine, Division of Endocrinology, Diabetes and Metabolism & Clinical Research CenterUniversity of Tennessee Health Science CenterMemphisUSA

Personalised recommendations